1
|
Stefanski M, Le Guern A, Visseaux L, Ehret M, Colomb M, Jeudy G, Le Duff F, Vourc'h M, Baroudjian B, Perea-Villacorta R, Bernigaud C, Mallet S, Norberciak L, Debarbieux S, Perrot JL, Grange F, Modiano P, Monnier J, Bahadoran P. Real-life practice of reflectance confocal microscopy in France: A prospective multicenter study. J Am Acad Dermatol 2024:S0190-9622(24)00383-9. [PMID: 38387851 DOI: 10.1016/j.jaad.2024.01.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 12/03/2023] [Accepted: 01/10/2024] [Indexed: 02/24/2024]
Abstract
BACKGROUND Studies demonstrating the potential utility of reflectance confocal microscopy (RCM) have been performed under experimental conditions. OBJECTIVE To provide an overview of RCM practice in real-life. METHODS A multicenter, prospective study carried out in 10 university dermatology departments in France. RESULTS Overall, 410 patients were enrolled. One-half of the patients (48%) were referred by private practice dermatologists. They were referred for diagnosis (84.9%) or presurgical mapping (13%). For diagnosis, the lesions were located on the face (62%), arms and legs (14.9%), and trunk (13.6%), and presurgical mapping was almost exclusively on the face (90.9%). Among those referred for diagnosis, the main indication was suspicion of a skin tumor (92.8%). Of these, 50.6% were spared biopsies after RCM. When RCM indicated surgery, histology revealed malignant lesions in 72.7% of cases. The correlation between RCM and histopathology was high, with a correlation rate of 82.76% and a kappa coefficient of 0.73 (0.63; 0.82). LIMITATIONS This study was performed in the settings of French tertiary referral hospitals. CONCLUSION This study shows that in real-life RCM can be integrated into the workflow of a public private network, which enables a less invasive diagnostic procedure for patients.
Collapse
Affiliation(s)
- Marion Stefanski
- Department of Oncodermatology, Reims University Hospital, Reims France; Department of Dermatology, Saint Vincent de Paul Hospital, Hospital Group of the Catholic Institute of Lille, Lille, France
| | - Aurore Le Guern
- Department of Dermatology, Saint Vincent de Paul Hospital, Hospital Group of the Catholic Institute of Lille, Lille, France
| | | | - Marine Ehret
- Department of Dermatology, Emile Muller Hospital, Mulhouse, France
| | - Michel Colomb
- Department of Oncodermatology, Reims University Hospital, Reims France
| | - Géraldine Jeudy
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Florence Le Duff
- Department of Dermatology, Nice University Hospital, Nice, France
| | - Morgane Vourc'h
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | | | - Rosa Perea-Villacorta
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | | | - Stéphanie Mallet
- Department of Dermatology and Skin Cancers, La Timone Hospital, AP-HM, Aix-Marseille University, Marseille, France
| | - Laurène Norberciak
- Delegation of Clinical Research and Innovation, Biostatistics, Saint Philibert Hospital, Catholic University of Lille, Lille, France
| | | | - Jean-Luc Perrot
- Department of Dermatology, Saint Etienne University Hospital et Laboratoire Hubert Curien UMR CNRS 5516, Saint Etienne, France
| | - Florent Grange
- Department of Dermatology, Valence Hospital, Valence, France
| | - Philippe Modiano
- Department of Dermatology, Saint Vincent de Paul Hospital, Hospital Group of the Catholic Institute of Lille, Lille, France
| | - Jilliana Monnier
- Department of Dermatology and Skin Cancers, La Timone Hospital, AP-HM, Aix-Marseille University, Marseille, France
| | | |
Collapse
|
2
|
Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S. Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study. J Eur Acad Dermatol Venereol 2024; 38:e71-e73. [PMID: 37595320 DOI: 10.1111/jdv.19435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/11/2023] [Indexed: 08/20/2023]
Affiliation(s)
- K Khelef
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - E Maubec
- Service de Dermatologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France
- Campus de Bobigny-Université Sorbonne Paris Nord, Bobigny, France
- UMR 1124, Campus Saint Germain des Prés, Paris, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - B Bonniaud
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - A Pham-Ledard
- Service de Dermatologie, CHU de Bordeaux, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - F Herms
- Service de Dermatologie, Hôpital Saint-Louis, APHP, Paris, France
| | - F Aubin
- Service de Dermatologie, INSERM 1098, CHU de Besançon de Franche Comté, Besançon, France
- Université de Bourgogne-Franche-Comté, Besançon, France
| | - N Beneton
- Service de Dermatologie, CH du Mans, Le Mans, France
| | - M Dinulescu
- Service de Dermatologie, Hôpital Pontchaillou, Rennes, France
| | - A Jannic
- Service de Dermatologie, Hôpital Henri-Mondor, APHP, Créteil, France
| | - A Duval-Modeste
- Service de Dermatologie, Hôpital Charles-Nicolle, Rouen, France
| | - E Archier
- Service de Dermatologie, Hôpital Saint-Joseph, Marseille, France
| | - C Berthin
- Service de Dermatologie, CHU d'Angers, Angers, France
| | - F Grange
- Service de Dermatologie, CHU de Reims, Reims, France
| | - J Arnault
- Service de Dermatologie, CHU Amiens-Picardie, Amiens, France
| | - V Heidelberger
- Service de Dermatologie, CH Robert-Ballanger, Aulnay-sous-Bois, France
| | - M Moncourier
- Service de Dermatologie, CHU de Grenoble-Alpes, Grenoble, France
| | - S Mansard
- Service de Dermatologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - R Triller
- Service de Dermatologie, Institut Franco-Britannique, Levallois-Perret, France
| | - M Pracht
- Groupe Hospitalier de St-Malo, Saint-Malo, France
| | - M Dumas
- Service de Dermatologie, CH René-Dubos, Pontoise, France
| | - O Lauche
- Clinique Clémentville, Montpellier, France
| | - L Mortier
- Service de Dermatologie, CHU de Lille, Lille, France
- INSERM U 1189, Université de Lille, Lille, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - S Dalac Rat
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| |
Collapse
|
3
|
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, Peuvrel L, Rouanet J, Brunet-Possenti F, Gerard E, Seris A, Jouary T, Saint-Jean M, Puyraveau M, Saiag P, Aubin F. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). Cancers (Basel) 2023; 15:3564. [PMID: 37509227 PMCID: PMC10377277 DOI: 10.3390/cancers15143564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/07/2023] [Accepted: 06/29/2023] [Indexed: 07/30/2023] Open
Abstract
BACKGROUND The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature. PATIENTS AND METHODS In this retrospective multicenter national real-life study, we enrolled patients who had been rechallenged with an ICI after achieving disease control with a first course of ICI, which was subsequently interrupted. The primary objective was to evaluate tumor response, while the secondary objectives included assessing the safety profile, identifying factors associated with tumor response, and evaluating survival outcomes. RESULTS A total of 85 patients from 12 centers were included in the study. These patients had advanced (unresectable stage III or stage IV) melanoma that had been previously treated and controlled with a first course of ICI before undergoing rechallenge with ICI. The rechallenge treatments consisted of pembrolizumab (n = 44, 52%), nivolumab (n = 35, 41%), ipilimumab (n = 2, 2%), or ipilimumab plus nivolumab (n = 4, 5%). The best overall response rate was 54%. The best response was a complete response in 30 patients (35%), a partial response in 16 patients (19%), stable disease in 18 patients (21%) and progressive disease in 21 patients (25%). Twenty-eight adverse events (AEs) were reported in 23 patients (27%), including 18 grade 1-2 AEs in 14 patients (16%) and 10 grade 3-4 AEs in nine patients (11%). The median progression-free survival (PFS) was 21 months, and the median overall survival (OS) was not reached at the time of analysis. Patients who received another systemic treatment (chemotherapy, targeted therapy or clinical trial) between the two courses of ICI had a lower response to rechallenge (p = 0.035) and shorter PFS (p = 0.016). CONCLUSION Rechallenging advanced melanoma patients with ICI after previous disease control induced by these inhibitors resulted in high response rates (54%) and disease control (75%). Therefore, ICI rechallenge should be considered as a relevant therapeutic option.
Collapse
Affiliation(s)
- Charlée Nardin
- Service de Dermatologie, Centre Hospitalier Universitaire, 25000 Besancon, France
- Université Franche Comté, Inserm 1098 RIGHT, 25020 Besancon, France
| | - Aymeric Hennemann
- Service de Dermatologie, Centre Hospitalier Universitaire, 25000 Besancon, France
| | - Kadiatou Diallo
- Centre de Méthodologie Clinique, Centre Hospitalier Universitaire, 25030 Besancon, France
| | - Elisa Funck-Brentano
- Université Paris-Saclay, UVSQ, EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Ambroise-Paré, Service de Dermatologie Générale et Oncologique, 92104 Boulogne-Billancourt, France
| | - Eve Puzenat
- Service de Dermatologie, Centre Hospitalier Universitaire, 25000 Besancon, France
| | | | - Géraldine Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire, Hôpital Le Bocage, 21079 Dijon, France
| | - Mahtab Samimi
- Service de Dermatologie, Centre Hospitalier Universitaire, BIP 1282, INRA-Université de Tours, 37020 Tours, France
| | - Candice Lesage
- Service de Dermatologie, Centre Hospitalier Universitaire, 34295 Montpellier, France
| | - Lise Boussemart
- Service de Dermatologie, Centre Hospitalier Universitaire, Université de Nantes, INSERM, Immunology and New Concepts in Immunotherapy, INCIT, UMR 1302, 44000 Nantes, France
| | - Lucie Peuvrel
- Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France
| | - Jacques Rouanet
- Service de Dermatologie, Centre Hospitalier Universitaire, 63003 Clermont-Ferrand, France
| | | | - Emilie Gerard
- Service de Dermatologie, Centre Hospitalier Universitaire, 33075 Bordeaux, France
| | - Alice Seris
- Oncologie Médicale, Centre Hospitalier, 64046 Pau, France
| | - Thomas Jouary
- Oncologie Médicale, Centre Hospitalier, 64046 Pau, France
| | | | - Marc Puyraveau
- Centre de Méthodologie Clinique, Centre Hospitalier Universitaire, 25030 Besancon, France
| | - Philippe Saiag
- Université Paris-Saclay, UVSQ, EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Ambroise-Paré, Service de Dermatologie Générale et Oncologique, 92104 Boulogne-Billancourt, France
| | - François Aubin
- Service de Dermatologie, Centre Hospitalier Universitaire, 25000 Besancon, France
- Université Franche Comté, Inserm 1098 RIGHT, 25020 Besancon, France
| |
Collapse
|
4
|
Geoffrois L, Harlé A, Sahki N, Sikanja A, Granel-Brocard F, Hervieu A, Mortier L, Jeudy G, Michel C, Nardin C, Huin-Schohn C, Merlin JL. Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol. BMC Cancer 2023; 23:554. [PMID: 37328818 DOI: 10.1186/s12885-023-11029-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Accepted: 05/30/2023] [Indexed: 06/18/2023] Open
Abstract
BACKGROUND With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at one year is approximately 30% and justify extensive research of predictive biomarkers. If in metastatic disease, the follow-up of circulating tumor DNA (ctDNA) has been demonstrated, its interest in adjuvant setting remains to be precised, especially because of a lower detection rate. Further, the definition of a molecular response could prove useful to personalized treatment. METHODS PERCIMEL is an open prospective multicentric study executed through collaboration of the Institut de Cancérologie de Lorraine (non-profit comprehensive cancer center) and 6 French university and community hospitals. A total of 165 patients with resected stage III and IV melanoma, eligible to adjuvant imunotherapy or anti-BRAF/MEK kinase inhibitors will be included. The primary endpoint is the presence of ctDNA, 2 to 3 weeks after surgery, defined as mutated ctDNA copy number calculated as the allelic fraction of a clonal mutation relative to total ctDNA. Secondary endpoints are recurrence-free survival, distant metastasis-free survival and specific survival. We will follow ctDNA along treatment, quantitatively through ctDNA mutated copy number variation, qualitatively through the presence of cfDNA and its clonal evolution. Relative and absolute variations of ctDNA during follow-up will be also analyzed. PERCIMEL study aims at provide scientific evidence that ctDNA quantitative and qualitative variations can be used to predict the recurrence of patients with melanoma treated with adjuvant immunotherapy or kinase inhibitors, thus defining the notion of molecular recurrence.
Collapse
Affiliation(s)
- Lionnel Geoffrois
- Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France
| | - Alexandre Harlé
- Biopathology Department, Institut de Cancérologie de Lorraine, CNRS UMR7039 CRAN Université de Lorraine, Vandoeuvre Les Nancy, France
| | - Nassim Sahki
- Methodology Biostatistics Unit, Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France
| | - Aleksandra Sikanja
- Clinical Research Department, Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France
| | | | - Alice Hervieu
- Medical Oncology Department, Centre Georges François Leclerc, Dijon, France
| | - Laurent Mortier
- Dermatology Department CHRU Lille, Inserm U1189, Université de Lille, Lille, France
| | | | - Catherine Michel
- Dermatology Department, GHR Mulhouse Sud Alsace, Mulhouse, France
| | - Charlée Nardin
- Dermatology Department CHU Besançon, Inserm 1098 RIGHT Université Franche Comté, Besançon, France
| | - Cécile Huin-Schohn
- Clinical Research Department, Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France
| | - Jean-Louis Merlin
- Biopathology Department, Institut de Cancérologie de Lorraine, CNRS UMR7039 CRAN Université de Lorraine, Vandoeuvre Les Nancy, France.
- Clinical Research Department, Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France.
| |
Collapse
|
5
|
Vuillamy C, Arnault JP, Fumery M, Mortier L, Monestier S, Mansard S, Bens G, Duval-Modeste AB, Funck-Brentano E, Jeudy G, Machet L, Chaby G, Dadban A, Lok C. Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature. Melanoma Res 2023; 33:192-198. [PMID: 36995276 PMCID: PMC10144273 DOI: 10.1097/cmr.0000000000000878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
Immunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor-induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficile infection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficile should be carried out for all patients with diarrhea who are being treated with immunotherapy.
Collapse
Affiliation(s)
| | | | - Mathurin Fumery
- Gastroenterology, CHU Amiens Picardie University Hospital, Amiens
| | | | - Sandrine Monestier
- Department of Dermatology, Marseille University Hospital (APHM), Marseille
| | - Sandrine Mansard
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand
| | - Guido Bens
- Department of Dermatology, Orléans University Hospital, Orléans
| | | | - Elisa Funck-Brentano
- Department of General and Oncologic Dermatology, Ambroise Paré Hospital (APHP), Boulogne-Billancourt
| | | | - Laurent Machet
- Department of Dermatology, Tours Regional University Hospital, Tours, France
| | | | | | | |
Collapse
|
6
|
Frazao A, Rethacker L, Jeudy G, Colombo M, Pasmant E, Avril MF, Toubert A, Moins-Teisserenc H, Roelens M, Dalac S, Maubec E, Caignard A. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis. J Immunother Cancer 2021; 8:jitc-2019-000275. [PMID: 32912923 PMCID: PMC7482503 DOI: 10.1136/jitc-2019-000275] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/14/2020] [Indexed: 12/11/2022] Open
Abstract
Background Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine–threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a BRAFV600E/K mutation. However, acquired resistance occurs in the majority of patients, leading to relapse. Immunotherapies that activate immune cytotoxic effectors induce long-lasting responses in 30% of patients. In that context, combination of targeted therapies with immunotherapy (IT) is a promising approach. We considered boosting natural killer (NK) cell tumor immunosurveillance, as melanoma cells express stress-induced molecules and activate NK cell lysis. Methods Here we have generated vemurafenib (a BRAF inihibitor)-resistant (R) cells from BRAFV600E SK28 and M14-sensitive (S) melanoma cell lines and investigated how resistance interferes with immunogenicity to NK cells. We determined the levels of several soluble molecules including NK ligands in 61 melanoma patients at baseline and 6 months M post-treatment with targeted therapies or immunotherapies. Results Vemurafenib resistance involved activation of p-AKT in SK28R and of p-MEK/p-ERK in M14R cells and was accompanied by modulation of NK ligands. Compared with S cells, SK28R displayed an increased expression of natural killer group 2 D (NKG2D) receptor ligands (major histocompatibility complex class (MHC) I chain-related protein A (MICA) and UL16-binding protein 2 (ULBP2)) whereas M14R exhibited decreased ULBP2. SK28R and M14R cells induced higher NK degranulation and interferon gamma secretion and were more efficiently lysed by donor and patient NK cells. SK28R showed increased tumor necrosis factor-related apoptosis-inducing ligand receptor II (TRAIL-RII) expression and TRAIL-induced apoptosis, and TRAIL-induced apoptosis of M14R was decreased. Combined BRAF/MEK inhibitors abrogated the growth of SK28S, M14S, and M14R cells, while growth of SK28R was maintained. BRAF/MEK inhibition attenuated NK activity but R cell lines activated polyfunctional NK cells and were lysed with high efficiency. We investigated the relationship of soluble NK ligands and response to treatment in a series of melanoma patients. Soluble NKG2D ligands known to regulate the receptor function have been associated to cancer progression. Serum analysis of patients treated with target therapies or IT indicates that soluble forms of NK ligands (MICA, B7H6, programmed cell death ligand 1, and carcinoembryonic antigen cell adhesion molecule 1) may correlate with clinical response. Conclusion These results support strategies combining targeted therapies and NK-based immunotherapies.
Collapse
Affiliation(s)
- Alexandra Frazao
- Université de Paris, INSERM UMRS-1160, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - Louise Rethacker
- Université de Paris, INSERM UMRS-1160, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - Géraldine Jeudy
- University Hospital Centre Dijon Bocage Complex, Dermatology Department, Dijon, France
| | - Marina Colombo
- Université de Paris, INSERM UMRS-1160, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - Eric Pasmant
- Université de Paris, AP-HP Hôpital Cochin, Genetic and Molecular Biology Department, Institut Cochin, Paris, France
| | - Marie-Françoise Avril
- Université de Paris, AP-HP Hôpital Cochin, Dermatology Department, Institute Cochin, Paris, France
| | - Antoine Toubert
- Université de Paris, INSERM UMRS-1160, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - Helene Moins-Teisserenc
- Université de Paris, INSERM UMRS-1160, AP-HP hopital Saint-Louis, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - Marie Roelens
- Université de Paris, INSERM UMRS-1160, AP-HP hopital Saint-Louis, Institut de Recherche Saint-Louis, 75010, Paris, France
| | - Sophie Dalac
- University Hospital Centre Dijon Bocage Complex, Dermatology Department, Dijon, France
| | - Eve Maubec
- Université de Paris 13, AP-HP Hôpital Avicenne, Dermatology Department, Bobigny, France
| | - Anne Caignard
- Université de Paris, INSERM UMRS-1160, Institut de Recherche Saint-Louis, 75010, Paris, France
| |
Collapse
|
7
|
Weill A, Brunet-Possenti F, Léonard-Louis S, Delyon J, Bonniaud B, Jeudy G, Descamps V, Dinulescu M, Le Corre Y, Psimaras D, Baroudjian B, Hervier B. Myopathies inflammatoires induites par les inhibiteurs de point de contrôle immunitaire : spectre clinique et traitements. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Weill A, Le Corre Y, Brunet-Possenti F, Léonard-Louis S, Delyon J, Bonniaud B, Jeudy G, Descamps V, Dinulescu M, Psimaras D, Baroudjian B, Hervier B. Myopathies inflammatoires induites par les inhibiteurs de point de contrôle immunitaire : la reprise d’une immunothérapie est possible. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Juzot C, Sibaud V, Amatore F, Mansard S, Seta V, Jeudy G, Pham-Ledard A, Benzaquen M, Peuvrel L, Le Corre Y, Lesage C, Viguier M, Baroudjian B, Dréno B, Quéreux G. Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study. J Eur Acad Dermatol Venereol 2021; 35:e511-e514. [PMID: 33783881 DOI: 10.1111/jdv.17253] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- C Juzot
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - V Sibaud
- Oncodermatology, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France
| | - F Amatore
- Department of dermatology, Timone Hospital, Aix-Marseille University, Marseille, France
| | - S Mansard
- Department of Dermatology, University Hospital Estaing, Clermont Ferrand, France
| | - V Seta
- Department of Dermatology, Cochin University Hospital, Paris, France
| | - G Jeudy
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - A Pham-Ledard
- Inserm U1053, Department of Dermatology, Bordeaux University Hospital, University of Bordeaux, Bordeaux, France
| | - M Benzaquen
- Department of Dermatology, Hôpital Nord, Aix-Marseille University, Marseille, France
| | - L Peuvrel
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Y Le Corre
- Department of Dermatology, Angers University Hospital, Angers, France
| | - C Lesage
- Department of Dermatology, Montpellier University Hospital, Montpellier, France
| | - M Viguier
- Department of Dermatology, Robert Debré University Hospital, Reims University, Reims, France
| | - B Baroudjian
- Department of Dermatology, Saint-Louis University Hospital, Paris, France
| | - B Dréno
- Department of Dermatology, CIC 1413, CRCINA, Nantes University Hospital, Nantes, France
| | - G Quéreux
- Department of Dermatology, CIC 1413, CRCINA, Nantes University Hospital, Nantes, France
| |
Collapse
|
10
|
Weill A, Delyon J, Descamps V, Deschamps L, Dinulescu M, Dupuy A, Célérier P, Nardin C, Aubin F, Le Corre Y, Heidelberger V, Maubec E, Malissen N, Longvert C, Machet L, Gounant V, Brosseau S, Bonniaud B, Jeudy G, Psimaras D, Doucet L, Lebbe C, Zalcman G, De Masson A, Baroudjian B, Leonard-Louis S, Hervier B, Brunet-Possenti F. Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: A national multicenter study. Rheumatology (Oxford) 2021; 60:5753-5764. [PMID: 33725115 DOI: 10.1093/rheumatology/keab249] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 03/04/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyze the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICI) rechallenge. METHODS We conducted a nationwide retrospective study between April 2018 and March 2020 including irM without myocardial involvement. Depending on the presence of cutaneous signs or unusual histopathological features, patients were classified into two groups: typical or atypical irM. Therapeutic strategies were analyzed in both groups. The modalities and outcomes of ICI rechallenge were reviewed. RESULTS Among the 20 patients, 16 presented typical irM. Regardless of severity, most typical irM were treated with steroid monotherapy (n = 14/16) and all had a complete response within ≤ 3 weeks. The efficacy of oral steroids for non-severe typical irM (n = 10) was the same with low-dose (≤ 0.5 mg/kg/day) or high-dose (1 mg/kg/day). Severe typical irM were successfully treated with intravenous methylprednisolone. Atypical irM (n = 4) had a less favorable evolution, including one irM-related death, and required heavy immunosuppression. ICI were safely reintroduced in 9 patients presenting a moderate (n = 6) or a severe (n = 3) irM. CONCLUSION Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favor of a safe reintroduction of ICI following symptom resolution and CK normalization in moderate and severe forms of irM.
Collapse
Affiliation(s)
- Amandine Weill
- Department of Dermatology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Julie Delyon
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Vincent Descamps
- Department of Dermatology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Lydia Deschamps
- Department of Pathology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Monica Dinulescu
- Department of Dermatology, CHU de Rennes, Université de Rennes, Rennes, France
| | - Alain Dupuy
- Department of Dermatology, CHU de Rennes, Université de Rennes, Rennes, France
| | | | - Charlee Nardin
- Department of Dermatology, CHU de Besançon, Université de Franche Comté, Besançon, France
| | - François Aubin
- Department of Dermatology, CHU de Besançon, Université de Franche Comté, Besançon, France
| | - Yannick Le Corre
- Department of Dermatology, CHU d'Angers, Université LUNAM, Angers, France
| | - Valentine Heidelberger
- Department of Dermatology, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| | - Eve Maubec
- Department of Dermatology, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
| | - Nausicaa Malissen
- Department of Dermatology, Hôpital La Timone, AP-HM, Université d'Aix-Marseille, Marseille, France
| | - Christine Longvert
- Department of Dermatology, Hôpital Ambroise-Paré, AP-HP, Boulogne-Billancourt, France
| | - Laurent Machet
- Dermatology Department, CHRU de Tours, Université de Tours, Tours, France
| | - Valérie Gounant
- Department of Thoracic Oncology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Solenne Brosseau
- Department of Thoracic Oncology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Bertille Bonniaud
- Department of Dermatology, Hôpital universitaire de Dijon, Dijon, France
| | - Géraldine Jeudy
- Department of Dermatology, Hôpital universitaire de Dijon, Dijon, France
| | - Dimitri Psimaras
- Department of Neurology, Hôpital La Pitié Salpétrière, AP-HP, Université Sorbonne Paris Centre, Paris, France
| | - Ludovic Doucet
- Department of Oncology, Hôpital Saint Louis, AP-HP, Université 7, Paris, France
| | - Céleste Lebbe
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Gérard Zalcman
- Department of Thoracic Oncology, Hôpital Bichat, AP-HP, Université de Paris, Paris, France
| | - Adèle De Masson
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Barouyr Baroudjian
- Department of Dermatology, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | - Sarah Leonard-Louis
- Department of Neuropathology, Hôpital La Pitié Salpétrière, AP-HP, Université Sorbonne Paris Centre, Paris, France
| | - Baptiste Hervier
- Department of Internal Medicine, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France
| | | | | |
Collapse
|
11
|
Stefanski M, Monnier J, Le Guern A, Visseaux L, Ehret M, Colomb M, Jeudy G, Vourch M, Le Duff F, Norberciak L, Baroudjian B, Bernigaud C, Perea-Villacorta R, Mallet S, Debarbieux S, Perrot J, Grange F, Modiano P, Bahadoran P. Activité de microscopie confocale in vivo en France : étude observationnelle prospective multicentrique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Juzot C, Sibaud V, Amatore F, Mansard S, Seta V, Jeudy G, Pham-Ledard A, Benzaquen M, Dinulescu M, Le Corre Y, Lesage C, Viguier M, Baroudjian B, Clerc CJ, Funck-Brentano E, Giacchero D, Mortier L, Peuvrel L, Machet L, Duvert-Lehembre S, Viarnaud A, Joachim C, Bara C, Baubion E, Bergeret B, Brunet-Possenti F, Debarbieux S, Hébert V, Konstantinou MP, Marzouki-Zerouali A, Moreau-Huguen J, Phan C, Templier I, Celerier P, Aubin F, Modiano P, Poinas A, Vibet MA, Dréno B, Quéreux G. Pemphigoïdes bulleuses associées aux anti-PD-1/PDL-1 : étude nationale de 85 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Font G, Staumont-Salle D, Oro S, Seta V, Dupin N, Richard M, Jeudy G, Mallet S, Alexandre M, Le Roux-Villet C, Joly P, Prost-Squarcioni C, Duvert-Lehembre S. Efficacité du rituximab dans les maladies à IgA linéaire : une cohorte rétrospective. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Briand C, Gourier G, Poizeau F, Jelti L, Bachelerie M, Quéreux G, Jeudy G, Acquitter M, Ingen-Housz-Oro S, Caux F, Prost C, Darrigade AS, Heron Mermin D, Mahé E, Picart Dahan C, Richard MA, Clerc CJ, Salle De Chou C, Plée J, Abasq-Thomas C, Misery L, Brenaut E. Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study. Acta Derm Venereol 2020; 100:adv00320. [PMID: 33135772 PMCID: PMC9309871 DOI: 10.2340/00015555-3683] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Pruritus is a common symptom of bullous pemphigoid (BP), but has been poorly studied. The aim of this study was to analyse the characteristics of pruritus in patients with BP and its impact on their quality of life. A multicentre prospective observational study (in 15 French hospitals) was performed. A total of 60 patients were included, with a mean age of 77.4 years. Pruritus occurred daily in 85% of patients, with a mean pruritus intensity of 5.2/10. Tingling sensations were present in 72.4% of patients and burning sensations in 68.9%. Pruritus was exacerbated by stress, fatigue and xerosis. The mean ItchyQol score was 56.2/110 and the mean 5-D Itch Scale score was 16.5/25. The severity of pruritus was not related to age, sex, BP activity score, eosinophilia, or anti-BP230 and anti-BP180 autoantibodies. This study revealed that pruritus in BP is poorly tolerated and is an important cause of impaired quality of life.
Collapse
Affiliation(s)
- Clémence Briand
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Brest, FR-29609 Brest, France. E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Landais C, Prevel O, Jeudy G, Journet J, Goujon E, Collet E, Jordan M, Bonniaud B, Dalac S. Nécroses cutanées liées à une artériolopathie calcifiante non urémique (ACNU). Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Briand C, Gourier G, Poizeau F, Jelti L, Bachelerie M, Quéreux G, Jeudy G, Acquitter M, Oro S, Caux F, Darrigade A, Heron Mermin D, Mahé E, Picart Dahan C, Richard MA, Clerc C, Salle De Chou C, Bernard P, Abasq C, Misery L, Brenaut E. Caractéristiques du prurit dans la pemphigoïde bulleuse et impact sur la qualité de vie: l’étude prospective multicentrique PruriPB. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey. J Immunother 2019; 42:175-179. [PMID: 31090656 DOI: 10.1097/cji.0000000000000268] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Immune checkpoint inhibitors (ICI) significantly improve overall survival (OS) in patients with advanced melanoma, but immune-related colitis may occur and warrant anti-tumor necrosis factor α (TNFα) treatment in severe forms. A nationwide, multicenter retrospective survey was conducted to assess both, the real-life incidence of grade 3/4 ICI-induced colitis treated with anti-TNFα, in patients with advanced melanoma, and the consequence of this therapeutic strategy on disease outcome. All patients with advanced melanoma treated with anti-TNFα agents for severe ICI-related colitis in the participating centers were included. Relative incidence was calculated according to the total number of patients treated with ICI in network centers during the period of inclusion. The possible impact of anti-TNFα treatment on disease outcome was evaluated through comparison of objective response rate, progression-free survival, and OS with pivotal literature data. Twenty-seven patients from 13 tertiary referral centers were included. Overall, severe ICI-related colitis treated with anti-TNFα occurred in 1% of patients with advanced melanoma, mostly with ipilimumab. Infliximab was successfully used in all patients but 1, mostly after 1 infusion. OS and progression-free survival of 12 and 3 months, respectively, were observed in these patients, along with an objective response rate of 41% at 12 months. This survey shows a low real-life incidence of severe colitis requiring anti-TNFα. Response rates to immunotherapy and survival data do not appear to significantly differ from those observed in pivotal studies. Severe ICI-induced colitis requiring anti-TNFα treatment appears to be a rare event in advanced melanoma, and infliximab does not seem to adversely affect disease outcome.
Collapse
Affiliation(s)
| | - Christine Longvert
- Department of Dermatology, Ambroise-Paré Hospital, APHP, Boulogne-Billancourt
| | - Sorilla Prey
- CHU, Bordeaux, Department of Dermatology
- Inserm U-1035, University of Bordeaux, Bordeaux
| | | | | | - Laurent Machet
- Department of Dermatology, CHRU Tours and Inserm U1253, University of Tours, Tours
| | - Ouidad Zehou
- Department of Dermatology, University Hospital Henri Mondor, Créteil
| | - Nora Kramkimel
- Department of Dermatology, University Hospital Cochin, Paris
| | | | | | - François Aubin
- Department of Dermatology, University Hospital, Besançon
| | | | - Sandrine Mansard
- Department of Dermatology, University Hospital Estaing, Clermont Ferrand, France
| | | | - François-Xavier Lesage
- Epsylon, University Montpellier, Paul Valéry University Montpellier 3, University Hospital, Montpellier
| | | |
Collapse
|
18
|
Guillot B, Dupuy A, Pracht M, Jeudy G, Hindie E, Desmedt E, Jouary T, Leccia MT. Actualisation des données concernant le mélanome stade III : nouvelles recommandations du groupe français de cancérologie cutanée. Ann Dermatol Venereol 2019; 146:204-214. [DOI: 10.1016/j.annder.2019.01.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 01/15/2019] [Indexed: 11/16/2022]
|
19
|
Garel B, Ingen-Housz-Oro S, Afriat D, Prost-Squarcioni C, Tétart F, Bensaid B, Bara Passot C, Beylot-Barry M, Descamps V, Duvert-Lehembre S, Grootenboer-Mignot S, Jeudy G, Soria A, Valnet-Rabier MB, Barbaud A, Caux F, Lebrun-Vignes B. Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. Br J Clin Pharmacol 2019; 85:570-579. [PMID: 30511379 DOI: 10.1111/bcp.13827] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Revised: 11/08/2018] [Accepted: 11/23/2018] [Indexed: 11/27/2022] Open
Abstract
AIMS Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs. METHODS Data for patients with DILAD were collected retrospectively from the French Pharmacovigilance network (from 1985 to 2017) and from physicians involved in the Bullous Diseases French Study Group and the French Investigators for Skin Adverse Reactions to Drugs. Drug causality was systematically determined by the French imputability method. RESULTS Of the 69 patients, 42% had mucous membrane involvement, 20% lesions mimicking toxic epidermal necrolysis (TEN), 21% eosinophil infiltrates and 10% keratinocytes necrosis. Direct immunofluorescence, in 80%, showed isolated linear IgA deposits. Vancomycin (VCM) was suspected in 39 cases (57%), 11 had TEN-like lesions, as compared with three without VCM suspected. Among the 33 patients with a single suspected drug, 85% had an intrinsic imputability score of I4. Among them, enoxaparin, minocycline and vibramycin were previously unpublished. For all patients, the suspect drug was withdrawn; 15 did not receive any treatment. First-line therapy for 31 patients was topical steroids. Among the 60 patients with available follow-up, 52 achieved remission, 10 without treatment. Four patients experienced relapse, four died and five had positive accidental rechallenges. CONCLUSIONS There is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.
Collapse
Affiliation(s)
- Bethsabée Garel
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris (APHP), Henri-Mondor Hospital, 94010, Créteil, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris (APHP), Henri-Mondor Hospital, 94010, Créteil, France.,EA 7379 EpiDermE, Université Paris Est Créteil Val de Marne UPEC, Créteil, France.,Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France
| | - Daniele Afriat
- Regional Center of Pharmacovigilance, APHP, Pitié-Salpêtrière Hospital, Paris, France
| | - Catherine Prost-Squarcioni
- Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Pathology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France
| | - Florence Tétart
- Department of Dermatology, Rouen University Hospital, Rouen, France
| | - Benoit Bensaid
- Drug Allergy Unit-CCR2A, Department of Allergy and Clinical Immunology, CHU Lyon-Sud, Pierre Benite, France
| | | | - Marie Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - Vincent Descamps
- Department of Dermatology, APHP, Bichat Claude Bernard Hospital, Paris Diderot University
| | | | | | - Géraldine Jeudy
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Angèle Soria
- Department of Dermatology and Allergology, APHP, Tenon Hospital, Paris, France.,Sorbonne Université, Faculté de Médecine Sorbonne Université, Paris, France.,Inserm, UMR 1135, Paris, France
| | | | - Annick Barbaud
- Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France.,Department of Dermatology and Allergology, APHP, Tenon Hospital, Paris, France.,Sorbonne Université, Faculté de Médecine Sorbonne Université, Paris, France
| | - Frédéric Caux
- Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France
| | - Bénédicte Lebrun-Vignes
- EA 7379 EpiDermE, Université Paris Est Créteil Val de Marne UPEC, Créteil, France.,Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France.,Regional Center of Pharmacovigilance, APHP, Pitié-Salpêtrière Hospital, Paris, France
| |
Collapse
|
20
|
Dhers M, Bonniaud B, Jeudy G, Faivre L, Vabres P. Suivi évolutif et diagnostic final des taches café-au-lait multiples du jeune enfant. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Clerc M, Pasteur J, Jeudy G, Huther M, Vabres P, Dalac S, Bonniaud B, Collet E. Toxidermies photo-aggravées aux immunoglobulines intraveineuses. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Chaplain L, Blom A, Samimi M, Guillot B, Jouary T, Grob JJ, Meyer N, Zehou O, Combemale P, Lebbé C, Jeudy G, Grange F, Lacour P, Dinulescu M, Granel Brocard F, Beneton N, Aubin F, Bens G, De Quatrebarbes J, Steff M, Arnault JP, Le Corre Y, Stefan A, D’Incan M, Kramkimel N, Leccia MT, Thomas Beaulieu D, Maubec E, Robert C, Dreno B, Wierzbicka-Hainaut E, Lenormand C, Saiag P, Mortier L. Carcinome de Merkel : état des lieux du réseau CARADERM. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
23
|
Dhers M, Bonniaud B, Leleu C, Vabres P, Jeudy G. Pemphigoïde gravidique persistante et résistante au traitement : à propos d’un cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
24
|
Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Jeudy G, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Ballon A, Porcher R, Lebbe C. Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Mignard C, Deschamps-Huvier A, Duval-Modeste AB, Dutriaux C, Khammari A, Avril MF, Mortier L, Lesimple T, Gaudy-Marqueste C, Lesage C, Machet L, Aubin F, Meyer N, Beneton Benhard N, Jeudy G, Montaudié H, Arnault JP, Leccia MT, Joly P, Oncology Research Group Of The French Society Of Dermatology S. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G. Republication de : Traitements des patients atteints de mélanome de stade III inopérable ou de stade IV. Société française de dermatologie. Bull Cancer 2018; 105:780-789. [DOI: 10.1016/j.bulcan.2018.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Crépin JC, Martinet J, Jeudy G, Aubriot Lorton MH, Chrétien ML, Huther M, Vabres P, Bonniaud B. Épidermolyse bulleuse acquise à IgM Kappa révélatrice d’une maladie de Waldenström. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Herms F, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Grob JJ, Guillot B, Jeudy G, Lambert J, Lebbé C, Mateus C, Meyer N, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Mouri M, Basset-Seguin N. Carcinomes basocellulaires localement avancés traités par vismodégib : devenir des rémissions complètes après arrêt du traitement. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Guillot B. Incidence et impact du traitement par anti-TNFα des colites sévères sous immunothérapie du mélanome : étude MECOLIT. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Plaquevent M, Tetart F, Fardet L, Oro S, Bernard P, Roussel A, Avenel-Audran M, Chaby G, D’incan M, Souteyrand P, Duvert-Lehembre S, Picard-Dahan C, Jeudy G, Labeille B, Morice C, Richard MA, Bourgault Villada I, Litrowski N, Bara C, Mahe E, Prost C, Alexandre M, Quereux G, Soria A, Thomas-Beaulieu D, Pauwels C, Joly P. Pemphigoïdes bulleuses associées aux gliptines : mythe ou réalité ? Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Bertrand A, Ofaiche J, Bernard P, Lipsker D, Saillard C, Granel-Brocard F, Jachiet M, Ledard AP, Aubin F, Avenel-Audran M, Chaby G, Jeudy G, Meunier L, Richard MA, Joly P, Guillot B, Dereure O. Place du rituximab dans les pemphigoïdes bulleuse et gestationnelle : étude rétrospective nationale multicentrique de 48 observations. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.088] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Palladini A, Huther M, Bonniaud B, Barra CC, Pottecher P, Casasnovas R, Legouge C, Dalac-Rat S, Vabres P, Jeudy G. Lymphome anaplasique CD30+ musculaire primitif à révélation cutanée. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.453] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Moris V, Chapuis A, Guillier D, Jeudy G, Huther M, Auffret N, Piroth L, Blot M. Necrotizing fasciitis caused by genogroup × Neisseria meningitidis. QJM 2017; 110:589-590. [PMID: 28911029 DOI: 10.1093/qjmed/hcx109] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Indexed: 11/12/2022] Open
Affiliation(s)
- V Moris
- Service de Chirurgie Maxillo-Faciale
| | | | | | | | | | | | - L Piroth
- Service de Maladies Infectieuses et Tropicales, CHU François Mitterand, Dijon, France
| | - M Blot
- Service de Maladies Infectieuses et Tropicales, CHU François Mitterand, Dijon, France
| |
Collapse
|
34
|
Auvens C, Bouldoires B, Jeudy G, Bonniaud B, Dalac S, Berthier S, Leguy-Seguin V, Pasteur J, Audia S, Nicolas B, Guilhem A, Bonnotte B. Conduite à tenir devant un cancer indifférencié mettant en jeu le pronostic vital. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Bertrand AS, Ofaiche J, Bernard P, Lipsker D, Saillard C, Granel-Brocart F, Jachiet M, Pham-Ledard A, Aubin F, Avenel-Audran M, Chaby G, Jeudy G, Meunier L, Richard MA, Joly P, Guillot B, Dereure O. Place du rituximab dans les pemphigoïdes bulleuse et gestationnelle : étude rétrospective nationale multicentrique de 48 observations. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Pasteur J, Boulitrop C, Collet E, Bou Assi E, Aussedat M, Jeudy G, Vabres P. Nécroses cutanées sévères aux points d’injection d’apomorphine. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, Pham-Ledard A, Charles J, Pérol M, Gérard E, Combemale P, Bonnet D, Sigal ML, Mahé E. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2016; 31:e254-e257. [PMID: 27739129 DOI: 10.1111/jdv.14011] [Citation(s) in RCA: 126] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J Bonigen
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - C Raynaud-Donzel
- Service de Pneumologie, Hôpital Victor Dupouy, Argenteuil, France
| | - J Hureaux
- Service de Pneumologie, Centre Hospitalier Universitaire, Angers, France
| | - N Kramkimel
- Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - A Blom
- Service de Dermatologie Générale et Oncologique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire François Mitterrand, Dijon, France
| | - A-L Breton
- Service de Dermatologie, Centre Hospitalier Universitaire de Lyon Sud, Lyon, France
| | - T Hubiche
- Unité de Dermatologie Infectiologie, Centre Hospitalier Intercommunal de Fréjus/Saint-Raphaël, Fréjus, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - D Legoupil
- Service de Dermatologie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France
| | - A Pham-Ledard
- Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - J Charles
- Service de Dermatologie, CHU Grenoble, Grenoble, France
| | - M Pérol
- Département de Cancérologie Médicale, Centre Léon Bérard, Lyon, France
| | - E Gérard
- Service de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - P Combemale
- Unité d'Onco-Dermatolgie, Centre Léon Bérard, Lyon, France
| | - D Bonnet
- Service de Dermatologie Générale et Oncologique, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - M-L Sigal
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - E Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | | |
Collapse
|
38
|
Gandon C, Bonniaud B, Collet E, Dalac S, Jeudy G, Vabres P. A Typical Vascular and Pigmentary Dermoscopic Pattern of Capillary Malformations in Capillary Malformation-Arteriovenous Malformation Syndrome: Report of Four Cases. Pediatr Dermatol 2016; 33:e337-41. [PMID: 27480194 DOI: 10.1111/pde.12937] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
We report dermoscopic characteristics of cutaneous capillary malformations in four patients with capillary malformation-arteriovenous malformation (CM-AVM) syndrome. We observed a mixed vascular and pigmentary pattern with branched linear vessels and an underlying homogeneous brown background. Disappearance of the vascular pattern on pressure revealed an underlying faint pigmentary reticular pattern. Our results suggest that this typical biphasic pattern on dermoscopy may be useful for the diagnosis of CM-AVM syndrome.
Collapse
Affiliation(s)
- Claudine Gandon
- Dermatology Department, Dijon University Hospital, Dijon, France
| | | | - Evelyne Collet
- Dermatology Department, Dijon University Hospital, Dijon, France
| | - Sophie Dalac
- Dermatology Department, Dijon University Hospital, Dijon, France
| | - Géraldine Jeudy
- Dermatology Department, Dijon University Hospital, Dijon, France
| | - Pierre Vabres
- Dermatology Department, Dijon University Hospital, Dijon, France.
| |
Collapse
|
39
|
Faivre C, Villani AP, Aubin F, Lipsker D, Bottaro M, Cohen JD, Durupt F, Jeudy G, Sbidian E, Toussirot E, Badot V, Barbarot S, Debarbieux S, Delaporte E, Goegebeur G, Morel J, Nassif A, Duru G, Jullien D. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol 2016; 74:1153-9. [PMID: 26965410 DOI: 10.1016/j.jaad.2016.01.018] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Revised: 01/06/2016] [Accepted: 01/12/2016] [Indexed: 10/22/2022]
Abstract
BACKGROUND Paradoxical hidradenitis suppurativa (HS) induced by biologic agents (BA) is scarcely reported. OBJECTIVE We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA. METHODS This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA. RESULTS We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients. LIMITATIONS Retrospective nature and lack of complete follow-up for some patients are limitations. CONCLUSION HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched.
Collapse
Affiliation(s)
- Coline Faivre
- Dermatology Department, Hôpital Edouard Herriot, Université Claude Bernard Lyon I, Lyon, France.
| | - Axel Patrice Villani
- Dermatology Department, Hôpital Edouard Herriot, Université Claude Bernard Lyon I, Lyon, France
| | - François Aubin
- Dermatology Department, Hôpital Saint-Jacques, Université de Franche-Comté, Besançon, France
| | - Dan Lipsker
- Dermatology Department, Centre Hospitalo-Universitaire (CHU) de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Martine Bottaro
- Rheumatology Department, Center Hospitalier de Valence, Valence, France
| | | | - François Durupt
- Dermatology Department, Center Hospitalier de Valence, Valence, France
| | | | - Emilie Sbidian
- Dermatology Department, CHU Henri-Mondor, Créteil, France
| | - Eric Toussirot
- Clinical Investigation Center for Biotherapy, Institut National de la Santé et de la Recherche Médicale (INSERM) Centre d'Investigation Clinique (CIC) 1431 and Rheumatology, Université de Franche-Comté, Besançon, France
| | - Valérie Badot
- Rheumatology Department, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | - Emmanuel Delaporte
- Dermatology Department, Hôpital Claude-Huriez, Université Lille II, Lille, France
| | - Guetty Goegebeur
- Hepatogastroenterology Department, Center Hospitalier Loire Vendée Océan, Challans, France
| | - Jacques Morel
- Rheumatology Department, CHU Lapeyronie, Université de Montpellier, Montpellier, France
| | - Aude Nassif
- Infectious Diseases Center Necker-Pasteur, Pasteur Institute, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gérard Duru
- Dermatology Department, Hôpital Edouard Herriot, Université Claude Bernard Lyon I, Lyon, France
| | - Denis Jullien
- Dermatology Department, Hôpital Edouard Herriot, Université Claude Bernard Lyon I, Lyon, France
| | | |
Collapse
|
40
|
Chami I, Dalle S, Leccia M, Lacour J, Mortier L, Jeudy G, Stoebner PE, Dréno B, Porcher R, Kowal A, Lebbé C. Métastases cérébrales de mélanome traitées par immunothérapies anti-PD1 : efficacité et tolérance. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
41
|
Gandon C, Bonniaud B, Collet E, Dalac S, Jeudy G, Vabres P. Taches café au lait associées aux angiomes plans du syndrome CM-AVM : aspect dermoscopique. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, Godmer P, Abasq C, Astudillo L, Belenotti P, Bessis D, Bigot A, Doutre MS, Ebbo M, Guichard I, Hachulla E, Héron E, Jeudy G, Jourde-Chiche N, Jullien D, Lavigne C, Machet L, Macher MA, Martel C, Melboucy-Belkhir S, Morice C, Petit A, Simorre B, Zenone T, Bouillet L, Bagot M, Frémeaux-Bacchi V, Guillevin L, Mouthon L, Dupin N, Aractingi S, Terrier B. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol 2015; 67:527-34. [PMID: 25385679 DOI: 10.1002/art.38956] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Accepted: 11/06/2014] [Indexed: 11/10/2022]
Abstract
OBJECTIVE Hypocomplementemic urticarial vasculitis (HUV) is an uncommon vasculitis of unknown etiology that is rarely described in the literature. We undertook this study to analyze the clinical spectrum and the therapeutic management of patients with HUV. METHODS We conducted a French nationwide retrospective study that included 57 patients with chronic urticaria, histologic leukocytoclastic vasculitis, and hypocomplementemia. We assessed clinical and laboratory data and evaluated the patients' cutaneous and immunologic responses to therapy. We evaluated treatment efficacy by measuring the time to treatment failure. RESULTS Urticarial lesions were typically more pruritic than painful and were associated with angioedema in 51% of patients, purpura in 35%, and livedo reticularis in 14%. Extracutaneous manifestations included constitutional symptoms (in 56% of patients) as well as musculoskeletal involvement (in 82%), ocular involvement (in 56%), pulmonary involvement (in 19%), gastrointestinal involvement (in 18%), and kidney involvement (in 14%). Patients with HUV typically presented with low C1q levels and normal C1 inhibitor levels, in association with anti-C1q antibodies in 55% of patients. Hydroxychloroquine or colchicine seemed to be as effective as corticosteroids as first-line therapy. In patients with relapsing and/or refractory disease, rates of cutaneous and immunologic response to therapy seemed to be higher with conventional immunosuppressive agents, in particular, azathioprine, mycophenolate mofetil, or cyclophosphamide, while a rituximab-based regimen tended to have higher efficacy. Finally, a cutaneous response to therapy was strongly associated with an immunologic response to therapy. CONCLUSION HUV represents an uncommon systemic and relapsing vasculitis with various manifestations, mainly, musculoskeletal and ocular involvement associated with anti-C1q antibodies, which were found in approximately half of the patients. The best strategy for treating HUV has yet to be defined.
Collapse
Affiliation(s)
- Marie Jachiet
- Hôpital Cochin, AP-HP, and Université Paris Descartes, Paris 5, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu A, Petrella T, Collet E, Vabres P. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br J Dermatol 2015; 172:1454-5. [PMID: 25384395 DOI: 10.1111/bjd.13522] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France.
| | - S Dalac-Rat
- Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France
| | - B Bonniaud
- Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France
| | - A Hervieu
- Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France
| | - T Petrella
- Service d'Anatomie Pathologique, Centre Hospitalier Universitaire, 21000, Dijon, France
| | - E Collet
- Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France
| | - P Vabres
- Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France
| |
Collapse
|
44
|
Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu A, Petrella T, Collet E, Vabres P. Syndrome de Lyell sous vémurafénib : substitution par dabrafénib sans récidive. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
45
|
Faivre C, Aubin F, Bottaro M, Cohen JD, Durupt F, Lipsker D, Debarbieux S, Jeudy G, Morel J, Toussirot E, Faure M, Jullien D. Apparition d’une maladie de Verneuil sous biothérapie : une série de 14 cas. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
46
|
Bonniaud B, Maudinas R, Jeudy G, Leleu C, Vabres P, Collet E. Guérison d’une urticaire d’effort après traitement d’une oxyurose. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Gandon C, Küry S, Jeudy G, Schmitt S, Thierry G, Bézieau S, Vabres P. Acrodermatite entéropathique par isodisomie uniparentale. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Bernigaud C, Collet E, Jeudy G, Hervieu A, Bruyère R, Djerad H, Couderc B, Combret S, Allanore L, Aubriot MH, Vabres P. Toxicité cutanée grave au docétaxel (Taxotère®) au cours d’une infection VIH : rôle des interactions médicamenteuses. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
Jeudy G, Gandon C, Aubriot-Lorton MH, Collet E, Dalac-Rat S, Vabres P. Lupus tuberculeux méconnu traité par photothérapie dynamique : application du principe de la lampe de Finsen. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Bou-Assi E, Bel B, Dalac S, Ferrari F, Jeudy G, Aubriot-Lorton MH, Collet E, Vabres P. Vascularite cutanée consécutive au traitement d’une gale profuse. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|